Adaptive design methods in clinical trials – a review

Abstract

In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular due to its flexibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent (ad hoc), and retrospective adaptive designs. An adaptive design allows modifications made to trial and/or statistical procedures of ongoing clinical trials. However, it is a concern that the actual patient population after the adaptations could deviate from the originally target patient population and consequently the overall type I error (to erroneously claim efficacy for an infective drug) rate may not be controlled. In addition, major adaptations of trial and/or statistical procedures of on-going trials may result in a totally different trial that is unable to address the scientific/medical questions the trial intends to answer. In this article, several commonly considered adaptive designs in clinical trials are reviewed. Impacts of ad hoc adaptations (protocol amendments), challenges in by design (prospective) adaptations, and obstacles of retrospective adaptations are described. Strategies for the use of adaptive design in clinical development of rare diseases are discussed. Some examples concerning the development of Velcade intended for multiple myeloma and non-Hodgkin's lymphoma are given. Practical issues that are commonly encountered when implementing adaptive design methods in clinical trials are also discussed.

Predicting dropout in dietary weight loss trials using demographic and early weight change characteristics: Implications for trial design

“…Here all participants are randomised at least once, however those who fail to respond at a predefined time point are further randomised into more than one treatment option. Adaptive designs where randomisation of incoming subjects in based on the early weight loss of existing subjects could also be considered 27 . The potential for the use of these designs in weight loss, sample size estimation and analysis is covered in detail in Almirall et al 26 .…”

Establishing an evaluation mode with multiple primary outcomes based on combination of diseases and symptoms in TCM clinical trials

“…An adaptive design is defined as a clinical trial design that uses accumulating data to decide on how to modify trial and/or statistical aspects of the study as it continues, without undermining the validity and integrity of the trial (30,31).…”

The future of oncology therapeutics

“…New study designs have emerged, such as basket and umbrella clinical trials, as well as dynamically evolving multiple-arm phase 1b/2 trials with hundreds of recruited patients and specific exploratory cohorts of different tumor types and pivotal trials with associated sub-studies. These novel designs coupled with the recent awareness and sensitization of regulatory agencies in improving the current system inefficacy are changing the paradigm of clinical cancer research [6][7][8][9]. As opposed to a classically based succession of phase 1 trials for dose finding and administration schedule, followed by phase 2 trials to check for antitumor activity and, lastly, phase 3 trials in which the drug was compared against the standard therapy for superiority and drug approval, it is now becoming a reality that the typical objectives, in earlyand late-phase investigation, are now obtained in a time continuum during the course of the initial trials that seek to be much more informative [7].…”